Qlife Holding AB (QLIFE) AI Stock Analysis

• Market Cap: €30.71M
• Dividend Yield: N/A
• Average Volume (3M): 95.64K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.45
• Revenue Growth: 131.58%
• EPS Growth: 98.36%
• Country: SE
• Employees: 3
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.62
• Shares Outstanding: 12,484,911
• 10 Day Avg. Volume: 77,220
• 30 Day Avg. Volume: 95,643
• PEG Ratio: -0.76
• Price to Book (P/B): -911.64
• Price to Sales (P/S): 26054.69
• P/FCF Ratio: -24.05
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €2.98
• Price Target Upside: 29.47% Upside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 0

• Rating: 39 Underperform
• Price Target: kr3.00 ▲(30.43% Upside)

Qlife Holding AB's overall stock score is heavily impacted by its poor financial performance, characterized by declining revenue, persistent losses, and negative equity. Technical analysis indicates bearish momentum, and the negative P/E ratio highlights valuation concerns. These factors collectively suggest significant risks and challenges for the company.

Qlife Holding AB Business Overview & Revenue Model

Company Description

Qlife Holding AB (publ), a med-tech company, manufactures and sells in-vitro diagnostic analyzers and reagents. The company offers Egoo.Health Platform, an integrated platform with a measuring instrument with disposable capsules and software, where each capsule contains a test for a specific biomarker or virus. Its biomarkers include C-reactive protein home-testing capsule, PHE/Phenylalanine for PKU patients, and Sars-CoV-2/Influenza multiplex for virus/bacteria tests. The company was incorporated in 2019 and is based in Helsingborg, Sweden.

How the Company Makes Money

QLIFE generates revenue primarily through the sale of its diagnostic products and services. The company has established a business model that includes direct sales to healthcare providers, hospitals, and clinics, as well as partnerships with pharmaceutical companies for co-development of diagnostic solutions. Additional revenue streams may come from licensing agreements and collaborations with research institutions, which are aimed at expanding the application of its technologies. Furthermore, Qlife may also benefit from grants and funding aimed at supporting innovative healthcare solutions.

Qlife Holding AB Financial Statement Overview

Summary

Qlife Holding AB faces considerable financial challenges with declining revenue, persistent losses, negative equity, and weak cash flows. The firm's high reliance on external financing and inability to generate positive cash flow or profit raises concerns about its long-term viability and financial health.

Income Statement

Qlife Holding AB has experienced significant challenges in its income statement with declining total revenue from 2021 onwards and continuous negative net income. The gross profit margin is positive but the net profit margin is negative due to high operational expenses. EBIT and EBITDA margins are also negative, reflecting operational inefficiencies and high costs relative to revenue.

Balance Sheet

The balance sheet indicates financial instability with negative stockholders' equity in 2023 and 2024, suggesting more liabilities than assets. The debt-to-equity ratio is unmanageable due to negative equity, and the equity ratio is also negative, highlighting high financial leverage risk and potential insolvency.

Cash Flow

Cash flow statements show a consistent negative free cash flow and operating cash flow, indicating cash outflows surpassing inflows. Despite high financing cash flow, the operating cash flow to net income ratio and free cash flow to net income ratio remain negative, suggesting that the company is heavily reliant on external financing to sustain operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	264.00K	50.00K	244.00K	17.99M	39.61M	20.75M
Gross Profit	-430.00K	-158.00K	-6.31M	-10.75M	44.54M	35.68M
EBITDA	-19.87M	-12.46M	-150.50M	-78.05M	-35.13M	-19.49M
Net Income	-46.49M	-55.98M	-159.96M	-93.14M	-38.80M	-20.20M
Balance Sheet
Total Assets	9.40M	11.64M	39.05M	192.65M	193.44M	127.19M
Cash, Cash Equivalents and Short-Term Investments	651.00K	2.71M	1.66M	14.55M	73.46M	20.82M
Total Debt	8.70M	8.70M	20.25M	52.44M	4.72M	3.96M
Total Liabilities	14.91M	13.07M	62.17M	101.50M	30.26M	37.64M
Stockholders Equity	-5.51M	-1.43M	-23.12M	91.15M	132.50M	89.55M
Cash Flow
Free Cash Flow	-39.15M	-54.17M	-62.64M	-90.67M	-52.82M	-43.66M
Operating Cash Flow	-14.86M	-37.37M	-41.80M	-47.73M	-26.05M	-16.83M
Investing Cash Flow	-24.29M	-16.80M	-20.84M	-42.94M	-26.77M	-26.83M
Financing Cash Flow	39.71M	55.23M	49.00M	32.73M	106.02M	58.91M

Qlife Holding AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:QLIFE, the sentiment is Negative. The current price of 2.3 is below the 20-day moving average (MA) of 2.70, below the 50-day MA of 3.29, and below the 200-day MA of 2.90, indicating a bearish trend. The MACD of -0.22 indicates Positive momentum. The RSI at 28.22 is Positive, neither overbought nor oversold. The STOCH value of 37.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:QLIFE.

Qlife Holding AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LXB	50 Neutral	kr93.97M	―	-60.20%	―	163.12%	30.50%
SPEC	39 Underperform	€73.36M	―	-19.36%	―	―	-61.38%
QLIFE	39 Underperform	€30.71M	―	―	―	131.58%	98.36%
HEART	34 Underperform	kr128.97M	―	―	―	―	―